Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Atorvastatin, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia
This study has been completed.
Study NCT00335504. Last updated on April 26, 2009.
Information provided by National Cancer Institute (NCI)
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Colorectal Cancer
Precancerous/Nonmalignant Condition
Additional conditions recognized in this trial
Colorectal Neoplasms
Precancerous Conditions
More general conditions related to this trial
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases
Interventions listed in this trial
oligofructose-enriched inulin
atorvastatin calcium
sulindac
placebo
Additional drug interventions recognized in this trial
Atorvastatin
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Anticholesteremic Agents
Antilipemic Agents
Antimetabolites
Antineoplastic Agents
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Mayo Clinic
National Cancer Institute (NCI)
Back to top of Main Content
